Tudor Investment Corp ET AL acquired a new stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) in the 2nd quarter, according to the company in its most recent filing with the SEC. The firm acquired 16,847 shares of the biopharmaceutical company’s stock, valued at approximately $470,000.
A number of other large investors have also recently bought and sold shares of ACAD. Envestnet Asset Management Inc. increased its stake in ACADIA Pharmaceuticals by 23.0% in the 1st quarter. Envestnet Asset Management Inc. now owns 3,296 shares of the biopharmaceutical company’s stock valued at $113,000 after buying an additional 617 shares during the last quarter. Oppenheimer Asset Management Inc. increased its stake in ACADIA Pharmaceuticals by 10.0% in the 2nd quarter. Oppenheimer Asset Management Inc. now owns 5,133 shares of the biopharmaceutical company’s stock valued at $143,000 after buying an additional 468 shares during the last quarter. PNC Financial Services Group Inc. increased its stake in ACADIA Pharmaceuticals by 138.8% in the 1st quarter. PNC Financial Services Group Inc. now owns 4,384 shares of the biopharmaceutical company’s stock valued at $150,000 after buying an additional 2,548 shares during the last quarter. Flagship Harbor Advisors LLC purchased a new stake in ACADIA Pharmaceuticals in the 1st quarter valued at about $202,000. Finally, Legato Capital Management LLC purchased a new stake in ACADIA Pharmaceuticals in the 2nd quarter valued at about $223,000. Hedge funds and other institutional investors own 97.10% of the company’s stock.
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) opened at 36.91 on Wednesday. The stock’s market capitalization is $4.52 billion. The company has a 50-day moving average of $36.35 and a 200-day moving average of $31.67. ACADIA Pharmaceuticals Inc. has a 1-year low of $20.68 and a 1-year high of $41.20.
ACADIA Pharmaceuticals (NASDAQ:ACAD) last announced its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.55) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.72) by $0.17. ACADIA Pharmaceuticals had a negative net margin of 485.14% and a negative return on equity of 62.08%. The business had revenue of $30.50 million during the quarter, compared to analysts’ expectations of $20.02 million. During the same period in the prior year, the company earned ($0.63) earnings per share. The firm’s revenue was up 30400.0% on a year-over-year basis. Analysts anticipate that ACADIA Pharmaceuticals Inc. will post ($2.53) earnings per share for the current fiscal year.
In other ACADIA Pharmaceuticals news, EVP Glenn Baity sold 38,097 shares of the company’s stock in a transaction that occurred on Thursday, July 20th. The shares were sold at an average price of $30.00, for a total transaction of $1,142,910.00. Following the completion of the sale, the executive vice president now directly owns 109,253 shares of the company’s stock, valued at $3,277,590. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Over the last ninety days, insiders have sold 116,426 shares of company stock valued at $4,100,885. 22.25% of the stock is owned by corporate insiders.
COPYRIGHT VIOLATION NOTICE: This piece was originally posted by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this piece can be read at https://stocknewstimes.com/2017/10/11/tudor-investment-corp-et-al-invests-470000-in-acadia-pharmaceuticals-inc-acad-stock.html.
Several equities research analysts have commented on the stock. Piper Jaffray Companies reiterated a “buy” rating and issued a $61.00 price objective (up previously from $54.00) on shares of ACADIA Pharmaceuticals in a research note on Thursday, October 5th. JMP Securities raised their price target on shares of ACADIA Pharmaceuticals from $47.00 to $50.00 and gave the stock an “outperform” rating in a research note on Thursday, October 5th. HC Wainwright restated a “buy” rating and set a $60.00 price target on shares of ACADIA Pharmaceuticals in a research note on Thursday, October 5th. Bank of America Corporation raised their price target on shares of ACADIA Pharmaceuticals from $40.00 to $46.00 and gave the stock a “positive” rating in a research note on Thursday, October 5th. Finally, Leerink Swann restated a “market perform” rating on shares of ACADIA Pharmaceuticals in a research note on Monday. Six equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $46.21.
ACADIA Pharmaceuticals Company Profile
ACADIA Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PD Psychosis).
Want to see what other hedge funds are holding ACAD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD).
Receive News & Ratings for ACADIA Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.